Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

NCT06048926 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Carrelizumab
DRUG: Paclitaxel injection
DRUG: Cisplatin
RADIATION: Concurrent chemoradiotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University